Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration for several pharmaceutical products, indicating a significant advancement in its product portfolio and market position in the pharmaceutical industry [1] Group 1: Product Approvals - The company has obtained the production registration approval for Aminophylline Tablets (100mg), classified as a Class 3 chemical drug, making it the third domestic company to receive such approval [1] - Aminophylline Tablets are primarily used for alleviating symptoms of bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema, and can also be used to treat asthma caused by cardiogenic pulmonary edema [1] - The company’s Aminophylline raw material has also been approved for use in marketed formulations by the National Medical Products Administration [1] Group 2: Additional Product Approvals - The company has secured production registration approvals for Salbutamol Inhalation Solution (0.5ml: 50μg) and Injection Adenosine Methionine (0.5g), classified as Class 3 and Class 4 chemical drugs, respectively [1] - Salbutamol Inhalation Solution is mainly used to relieve symptoms associated with bronchial asthma, chronic bronchitis, and emphysema based on airflow limitation [1] - Injection Adenosine Methionine is primarily used for treating intrahepatic cholestasis caused by liver cirrhosis and cholestasis during pregnancy [1]
石四药集团(02005.HK)：氨茶碱片等三药品获注册批件